Related references
Note: Only part of the references are listed.Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy
C. Berlin et al.
LEUKEMIA (2015)
The efficacy of novel B cell biologics as the future of SLE treatment: A review
Ameer Kamal et al.
AUTOIMMUNITY REVIEWS (2014)
Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity
Katrin S. Reiners et al.
BLOOD (2013)
Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy
Luca Bologna et al.
JOURNAL OF IMMUNOLOGY (2013)
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Sylvia Herter et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Properties of mouse and human IgG receptors and their contribution to disease models
Pierre Bruhns
BLOOD (2012)
4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia
Corina Buechele et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy
Caroline Veuillen et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses
Julia Hilpert et al.
JOURNAL OF IMMUNOLOGY (2012)
Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL)
C. Buechele et al.
LEUKEMIA (2012)
Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation
Benjamin J. Schmiedel et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Aberrant Expression of Functional BAFF-System Receptors by Malignant B-Cell Precursors Impacts Leukemia Cell Survival
Sara Maia et al.
PLOS ONE (2011)
Innate or Adaptive Immunity? The Example of Natural Killer Cells
Eric Vivier et al.
SCIENCE (2011)
CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells
Tina Baessler et al.
BLOOD (2010)
The clinical application of monoclonal antibodies in chronic lymphocytic leukemia
Samantha M. Jaglowski et al.
BLOOD (2010)
A Functional Receptor for B-Cell-Activating Factor Is Expressed on Human Acute Lymphoblastic Leukemias
Reshmi Parameswaran et al.
CANCER RESEARCH (2010)
Rituximab A Review of its Use in Chronic Lymphocytic Leukaemia, Low-Grade or Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
Gillian M. Keating
DRUGS (2010)
BELIMUMAB, A BLyS-SPECIFIC INHIBITOR FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
C. Espinosa et al.
DRUGS OF TODAY (2010)
Glucocorticoid-Induced Tumor Necrosis Factor Receptor-Related Protein Ligand Subverts Immunosurveillance of Acute Myeloid Leukemia in Humans
Tina Baessler et al.
CANCER RESEARCH (2009)
Effect of interleukin-2 on synthesis of B cell activating factor belonging to the tumor necrosis factor family (BAFF) in human peripheral blood mononuclear cells
Katsuya Suzuki et al.
CYTOKINE (2008)
Glucocorticoid-induced tumor necrosis factor receptor negatively regulates activation of human primary natural killer (NK) cells by blocking proliferative signals and increasing NK cell apoptosis
Baoying Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G
G. Maki et al.
LEUKEMIA (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells
Sandra Tuyaerts et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
Prospects for the use of NK cells in immunotherapy of human cancer
Hans-Gustaf Ljunggren et al.
NATURE REVIEWS IMMUNOLOGY (2007)
BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-κB pathway
Tomoyuki Endo et al.
BLOOD (2007)
An APRIL to remember: novel TNF ligands as therapeutic targets
SR Dillon et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Scoring proteomes with proteotypic peptide probes
B Kuster et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells
C Imai et al.
BLOOD (2005)
Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: Evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)
D Pende et al.
BLOOD (2005)
Monoclonal antibody therapy of cancer
GP Adams et al.
NATURE BIOTECHNOLOGY (2005)
Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL
B He et al.
JOURNAL OF IMMUNOLOGY (2004)
Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway
C Kern et al.
BLOOD (2004)
G-CSF-stimulated neutrophils are a prominent source of functional BLyS
P Scapini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Human CD25+ CD4+ T suppressor cell clones produce transforming growth factor β, but not interleukin 10, and are distinct from type 1 T regulatory cells
MK Levings et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival
AJ Novak et al.
BLOOD (2002)
Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase
M López-Fraga et al.
EMBO REPORTS (2001)